LawFinder.news
LawFinder.news

Delhi High Court Grants Ad-Interim Injunction Against Intas Pharma for Patent Infringement of Helsinn Healthcare's Chemotherapy Drug

LAW FINDER NEWS NETWORK | |
Delhi High Court Grants Ad-Interim Injunction Against Intas Pharma for Patent Infringement of Helsinn Healthcare's Chemotherapy Drug

Court restrains Intas from manufacturing and selling `NO-CINV' combipack, citing prima facie patent infringement and defendant's failure to challenge patent validity


In a significant judgment delivered on November 10, 2026, the Delhi High Court, presided over by Justice Manmeet Pritam Singh Arora, granted an ad-interim injunction in favor of Helsinn Healthcare SA and its Indian licensee against Intas Pharmaceutical Limited for alleged infringement of Indian Patent No. 426553. The suit patent relates to a pharmaceutical composition combining Netupitant and Palonosetron hydrochloride for treating Chemotherapy-Induced Nausea and Vomiting (CINV).


Helsinn Healthcare, the plaintiff, claimed that Intas had launched a generic product named `NO-CINV,' a combipack comprising two separate tablets containing Netupitant 300 mg and Palonosetron 0.5 mg, which falls within the scope of the plaintiff's patent claims. The plaintiffs acted swiftly upon discovering the alleged infringement through a market survey on November 7, 2026, issuing a cease-and-desist notice to Intas. However, no response was received, prompting the filing of the suit on November 9, 2026.


The defendant admitted to launching the product but argued that the patent lacked novelty as the individual substances were already known and their patents had expired. Intas contended that merely combining two known substances could not constitute a valid invention and sought an opportunity to respond before any injunction was granted. The defendant also relied on prior judgments where injunctions were denied or limited.


The Court, however, noted that the patent had been granted after scrutiny and rejection of pre-grant oppositions by other pharmaceutical companies, including Zydus Healthcare Limited. The validity challenge was pending but not stayed by any court order. The defendant failed to initiate any legal challenge to the patent's validity before launching the product, which was held against them.


Drawing from precedents, particularly a similar earlier decision involving a combipack of Netupitant and Palonosetron, the Court found that the defendant's product, though packaged as two separate tablets, constituted an integrated combination covered by the patent claims. The Court observed that the plaintiffs had made out a prima facie case for infringement, and the balance of convenience and risk of irreparable harm favored the plaintiffs.


Consequently, the Delhi High Court restrained Intas Pharmaceutical Limited, its directors, agents, and distributors, from manufacturing, selling, distributing, advertising, or otherwise dealing with the `NO-CINV' product or any other infringing product pending the next hearing scheduled for November 17, 2026. The Court also directed the defendant to file a detailed reply with supporting documents regarding sales and stock.


This injunction underscores the judiciary's proactive stance in protecting pharmaceutical patents and preventing premature market entry of potentially infringing generic drugs, emphasizing the importance for defendants to clear legal hurdles before launching products that may infringe existing patents.


Bottom Line:

Patent Law - Ad-interim injunction granted to restrain the defendant from manufacturing, selling, or dealing with the product allegedly infringing the plaintiff's patent, pending further adjudication.


Statutory provision(s):

Code of Civil Procedure, 1908 - Order 39 Rules 1 and 2, Order 11 Rules 1, 3, 5; Section 149, Section 151; Commercial Courts Act, 2015 - Section 12A; Bharatiya Sakshya Adhiniyam, 2023 - Section 63(4)(c)


Helsinn Healthcare SA v. Intas Pharmaceutical Limited, (Delhi) : Law Finder Doc Id # 3033581

Share this article: